TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson

Slides:

Advertisements

Similar presentations

Prognostic impact of Ki-67 in Croatian women with early breast cancer (single-institution prospective observational study) Ivan Bilić, Natalija Dedić Plavetić,

Advertisements

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

R. Michelle Sarin, MD Mentor: Jeffrey Fowler, MD

C Supplemental Figure S2.. C Supplemental Figure S2.

Table 2. Association between histology grade, lymph node status,

Picture 3. Higher grade tumors are more frequently Ki67 positive

Copyright © 2004 American Medical Association. All rights reserved.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Marcelo Calil Instituto Brasileiro de Controle do Câncer

A All patients Arm A Arm B Deaths/patients 21/30 7/10 14/20

Supporting Information for Meta-analysis

Supplementary Table 1. (A) S100β Validation set (n=76 ER-positive and ER-negative patients). (B) S100β Validation set (n=59 ER-positive patients). Association.

Figure S1. DCYTB expression is higher in ER+ than ER- patients

Figure 1 Comparison of tumor size at time of excision between axillary node-negative, axillary node-positive, and distant metastasis subgroups of basal-like.

Supplementary Figure 1 CD45 CD14 FSC CD123 HLA-DR CD11c Lineage

Covariate AD N (%) SCC N (%) p-values Sex 63/63 96/ M

Table 1 Case # Age at primary Biopsy (year) Age at metastasis

Diego M. Marzese, Dave S. B. Hoon, Kelly K. Chong, Francisco E

徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

A Comparative Performance Analysis of Multispectral and RGB Imaging on HER2 Status Evaluation for the Prediction of Breast Cancer Prognosis Wenlou Liu,

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis Diana Ramirez-Ardila, A. Mieke Timmermans,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts.

by Michael F. Leahy, and J. Harvey Turner

Molecular Therapy - Nucleic Acids

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer

Volume 19, Issue 11, Pages (November 2017)

Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma Takahiro Mimae,

Patients who have received chemotherapy (n=60)

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer David J. Stewart, MD, Maria I. Nunez, MD,

Volume 122, Issue 1, Pages (January 2002)

Katja Lundgren, Nicholas P

Disease-specific survival

Supplementary figure1. CK7 CK20 CDX2 DPEP1 Cut off value: 85%

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Volume 127, Issue 2, Pages (August 2004)

The Oncofetal Protein IMP3: A Useful Marker to Predict Poor Clinical Outcome in Neuroendocrine Tumors of the Lung Alessandro Del Gobbo, MD, Valentina.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Volume 151, Issue 1, Pages (October 2018)

Diego M. Marzese, Dave S. B. Hoon, Kelly K. Chong, Francisco E

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

Extratumoral Vascular Invasion Is a Significant Prognostic Indicator and a Predicting Factor of Distant Metastasis in Non-small Cell Lung Cancer Yoshihisa.

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors

FMRP is highly expressed in human breast cancer and distal metastasis FMRP expression on human TMAs containing normal and multi‐tumour tissues. FMRP is.

Expression and Mutational Status of c-kit in Thymic Epithelial Tumors

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Supplementary Fig S1, Zembutsu H et al.

Clinical Relevance of Our Multimodality Prognostic Score

It’s All in the “Swerve of the Curve”

GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR

Supplementary Figure S1

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Fig. 1. Kaplan-Meier curves for PFS and OS

Stage III Thymic Epithelial Neoplasms are Not Homogeneous with Regard to Clinical, Pathological, and Prognostic Features Min-Woong Kang, MD, PhD, Eung-Sirk.

PD-L1 expression by melanocytes is observed in geographic association with TILs but does not depend on BRAF V600E. PD-L1 expression by melanocytes is observed.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

(A) Survival curves according to clinical response.

Coincidence and prognostic significance of PD-1+ and CD103+ cells in HGSC. Serial sections from the 490-case TMA were stained with antibodies to CD103.

A. B. C. D. Above median: Below median:

Presentation transcript:

TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson <40 4060 >60 15 (60%) 56 (58,3%) 69 (71,9%) 10 (40%) 40 (41,7%) 27 (28,1%) 0,129 - 0,118 7 (70%) 33 (52,4%) 28 (60,9%) 3 (30%) 30 (47,6%) 18 (39,1%) 0,468 -0,012 43 (68,3%) 33 (73,3%) 20 (31,7%) 12 (26,7%) 0,850 -0,042 Histotype Ductal Non Ductal 120 (62,9) 22 (78,6) 71 (37,1) 6 (21,4) 0,103 - 0,110 66 (59,5%) 2 (25%) 45 (40,5%) 6 (75%) 0,057 79 (71,8%) 4 (50%) 31 (28,2%) 0,192 0,120 Menopausal state Pre Post 41 (52,6%) 99 (71,2%) 37 (47,4) 40 (28,8%) 0,006* -0,187 24 (51%) 44 (61,1%) 23 (49%) 28 (38,9%) 0,279 -0,099 30 (63,8%) 53 (74,6%) 17 (44,2%) 18 (25,4%) 0,208 -0,116 Tumor size 2 cm >25 >5 63 (64,9%) 60 (63,2%) 13 (72,2%) 34 (35,1%) 35 (36,8%) 5 (27,8%) 0,769 -0,018 26 (56,5%) 36 (63,2%) 4 (40%) 20 (43,5%) 21 (46,8%) 6 (60%) 0,369 0,028 31 (67,4%) 43 (75,4%) 15 (32,6%) 14 (24,6%) 0,493 -0,015 LNM Negative Positive 61 (60,4%) 58 (76,3%) 40 (39,6%) 18 (23,7%) 0,026* -0,168 29 (56,8%) 16 (51,6%) 22 (43,2%) 15 (48,4%) 0,643 0,051 36 (72%) 21 (67,7%) 14 (38%) 10 (32,3%) 0,683 0,045 Metastases 82 (66,7%) 31 (81,6%) 41 (33,3%) 7 (18,4%) 0,079 -0,138 26 (52%) 9 (64,3%) 24 (48%) 5 (35,7%) 0,414 -0,102 37 (74%) 11 (78,6%) 13 (26%) 3 (21,4%) 0,727 -0,044 Grade G1 G2 G3 2 (100%) 15 (68,2%) 116 (62,7%) 0 (0%) 7 (31,8%) 69 (37,3%) 0,494 0,068 7 (63,6%) 56 (55,5%) 4 (36,4%) 45 (44,5%) 0,603 0,049 70 (70%) 30 (30%) 0,664 -0,041 Ki-67 31 (83,8%) 107 (61,1%) 6 (16,2%) 68 (38,9%) 0,009* 0,180 55 (54,5%) 46 (45,5%) 0,087 0,159 0,508 0,062 BMI <30 30 48 (73,8%) 26 (74,3%) 17 (26,2%) 9 (25,7%) 0,962 -0,005 13 (52%) 8 (61,5%) 12 (48%) 5 (38,5%) 0,575 -0,091 18 (72%) 11 (84,6%) 7 (28%) 2 (15,4%) 0,386 -0,141 Diabetes No Yes 42 (82,4%) 13 (59,1%) 9 (17,6%) 9 (40,9) 0,034* 0,248 15 (45,5%) 5 (83,3%) 18 (54,5%) 1 (16,7%) 0,088 -0,273 23 (69,7%) 10 (30,3%) 0,495 -0,109 Glicemya <110 >110 43 (82,7%) 10 (58,8%) 9 (17,3%) 7 (41,2%) 0,043* 0,244 7 (50%) 7 (87,5%) 1 (12,5%) -0,375 0,601 -0,111 Status Alive Dead 66 (66,7%) 10 (66,7%) 33 (32,3%) 5 (32,3%) 1 0,000 22 (59,5%) 9 (52,9%) 15 (40,5%) 8 (47,1%) 0,653 0,061 28 (75,7%) 11 (64,7%) 9 (24,3%) 6 (35,3%) 0,403 0,114 Relapse 47 (61,8%) 42 (84%) 29 (38,2) 8 (16%) 0,008* -0,238 22 (64,7%) 5 (29,4%) 12 (35,3%) 12 (70,6%) 0,017* 0,333 26 (76,5%) 8 (23,5%) 0,650 0,064 Supplementary Table 1. Clinical pathological features of TNBC samples and statistical association with tumor and TIL PD-L1 expression. LNM=Lymph Node Metastasis.

Supplementary Figure 1: TIL PD-L1+ patients Kaplan-Meier curves: (a) Disease Free Survival (DFS) (p=0,391); (b) Overall Survival (OS) (p=0,630).

Supplementary Figure 2: Tumor/TIL PD-L1+ TNBC patients Kaplan-Meier curves: (a) Disease Free Survival (DFS) (p=417); (b) Overall Survival (OS) (p=615).

(A) (B) Supplementary Figure 3: PD-L1 staining in adjacent TMA cores from the same sample (10X) (A-B) with details of intra-tumor cells (20X) (A) and tumor invasive front (20X) (B).

(A) (B) (C) Supplementary Figure 4: Immunostaining of PD-L1 (A), CD3 (B) and CD20(C) proteins on the same sample (magnification 40X).

(A) (B) (C) Supplementary Figure 5:Cytoplasmic and cell membrane staining of PD-L1 protein: (A) magnification 10X; (B) magnification 20X; (C) magnification 40X.